Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP674860.RA5wLYo0vvHfE9D0iRTgc99H66QK6GzCkU7dc-GBDxRcY130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP674860.RA5wLYo0vvHfE9D0iRTgc99H66QK6GzCkU7dc-GBDxRcY130_assertion type Assertion NP674860.RA5wLYo0vvHfE9D0iRTgc99H66QK6GzCkU7dc-GBDxRcY130_head.
- NP674860.RA5wLYo0vvHfE9D0iRTgc99H66QK6GzCkU7dc-GBDxRcY130_assertion description "[In vitro assessment of targeting by the CNGRC/PEG/PEI/DNA vector carrying a beta-galactosidase (beta-Gal)-expressing plasmid showed as much as a 5-fold increase in transduction, relative to the untargeted PEG/PEI/DNA-betagal vector, of CD13-positive lung cancer, fibrosarcoma, bladder cancer, and human umbilical vein endothelial cells.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP674860.RA5wLYo0vvHfE9D0iRTgc99H66QK6GzCkU7dc-GBDxRcY130_provenance.
- NP674860.RA5wLYo0vvHfE9D0iRTgc99H66QK6GzCkU7dc-GBDxRcY130_assertion evidence source_evidence_literature NP674860.RA5wLYo0vvHfE9D0iRTgc99H66QK6GzCkU7dc-GBDxRcY130_provenance.
- NP674860.RA5wLYo0vvHfE9D0iRTgc99H66QK6GzCkU7dc-GBDxRcY130_assertion SIO_000772 15703489 NP674860.RA5wLYo0vvHfE9D0iRTgc99H66QK6GzCkU7dc-GBDxRcY130_provenance.
- NP674860.RA5wLYo0vvHfE9D0iRTgc99H66QK6GzCkU7dc-GBDxRcY130_assertion wasDerivedFrom befree-20140225 NP674860.RA5wLYo0vvHfE9D0iRTgc99H66QK6GzCkU7dc-GBDxRcY130_provenance.
- NP674860.RA5wLYo0vvHfE9D0iRTgc99H66QK6GzCkU7dc-GBDxRcY130_assertion wasGeneratedBy ECO_0000203 NP674860.RA5wLYo0vvHfE9D0iRTgc99H66QK6GzCkU7dc-GBDxRcY130_provenance.